Anlotinib Retrospective Study for Esophageal Cancer

Feng Wang

Status: Completed

Conditions: Esophageal Neoplasms

Treatments: Drug: Anlotinib

Study type: Observational

Funder types: Other

Identifiers

NCT05303740

L2021-Y348-001

Details and patient eligibility

About

The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.

Enrollment: 300 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Esophageal cancer diagnosed pathologically or clinically
• Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment

Exclusion criteria

None

Trial design

300 participants in 1 patient group

Anlotinib

Treatment:

Drug: Anlotinib